Checkmate Pharmaceuticals Gross Profit

Checkmate Pharmaceuticals (CMPI) currently reports a gross profit of $0 as of March 2022. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Checkmate Pharmaceuticals's gross profit history and peer comparisons.

Checkmate Pharmaceuticals's gross profit changed from $0 to $0 (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Checkmate Pharmaceuticals's gross profit of $0 is lower than the Healthcare sector average of $67B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Checkmate Pharmaceuticals reported $0 in gross profit as of March 2022. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Checkmate Pharmaceuticals, and consider following CMPI for alerts when major investors trade the stock.